Oral contraceptives in migraine

被引:19
作者
Allais, Gianni [1 ]
Gabellari, Ilaria Castagnoli [1 ]
De Lorenzo, Cristina [1 ]
Mana, Ornella [1 ]
Benedetto, Chiara [1 ]
机构
[1] Univ Turin, Womens Headache Ctr, Dept Gynecol & Obstet, I-10126 Turin, Italy
关键词
combined oral contraceptives; ischemic stroke; migraine; safety; thrombophilia; tolerability; FACTOR-V-LEIDEN; REPRODUCTIVE LIFE EVENTS; ISCHEMIC-STROKE RISK; YOUNG-WOMEN; PROTHROMBOTIC MUTATIONS; CEREBRAL-ISCHEMIA; AURA; DISEASE; ABNORMALITIES; HEADACHE;
D O I
10.1586/14737175.9.3.381
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Combined oral contraceptives are a safe and highly effective method of birth control, but they can also raise problems of clinical tolerability and/or safety in migraine patients. It is now commonly accepted that, in migraine with aura, the use of combined oral contraceptives is always contraindicated, and that their intake must also be suspended by patients suffering from migraine without aura if aura symptoms appear. The newest combined oral contraceptive formulations are generally well tolerated in migraine without aura, and the majority of migraine without aura sufferers do not show any problems with their use; nevertheless, the last International Classification of Headache Disorders identifies at least two entities evidently related to the use of combined oral contraceptives: exogenous hormone-induced headache and estrogen-withdrawal headache. As regards the safety, even if both migraine and combined oral contraceptive intake are associated with an increased risk of ischemic stroke, migraine without aura per se is not a contraindication for combined oral contraceptive use. Other risk factors (tobacco use, hypertension, hyperlipidemia, obesity and diabetes) must be carefully considered when prescribing combined oral contraceptives in migraine without aura patients, in particular in women aged over 35 years. Furthermore, the exclusion of a hereditary thrombophilia and of alterations of coagulative parameters should precede any decision of combined oral contraceptive prescription in migraine patients.
引用
收藏
页码:381 / 393
页数:13
相关论文
共 66 条
[1]  
ACOG Committee on Practice Bulletins-Gynecology, 2006, Obstet Gynecol, V107, P1453
[2]  
Allais Gianni, 2007, Expert Rev Neurother, V7, P1105, DOI 10.1586/14737175.7.9.1105
[3]   Oral contraceptive-induced menstrual migraine. Clinical aspects and response to frovatriptan [J].
Allais, Gianni ;
Bussone, Gennaro ;
Airola, Gisella ;
Borgogno, Paola ;
Gabellari, Ilaria Castagnoli ;
De Lorenzo, Cristina ;
Pavia, Elena ;
Benedetto, Chiara .
NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 1) :S186-S190
[4]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718
[5]   Is migraine associated with right-to-left shunt a separate disease? Results of the SAM study [J].
Anzola, G. P. ;
Meneghetti, G. ;
Zanferrari, C. ;
Adami, A. ;
Dinia, L. ;
Del Sette, M. .
CEPHALALGIA, 2008, 28 (04) :360-366
[6]   Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: A meta-analysis [J].
Baillargeon, JP ;
McClish, DK ;
Essah, PA ;
Nestler, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (07) :3863-3870
[7]   Migraine and the risk of stroke, TIA, or death in the UK [J].
Becker, Claudia ;
Brobert, Gunnar P. ;
Almqvist, Per M. ;
Johansson, Saga ;
Jick, Susan S. ;
Meier, Christoph R. .
HEADACHE, 2007, 47 (10) :1374-1384
[8]  
Becker WJ, 1999, NEUROLOGY, V53, pS19
[9]   Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale [J].
Botto, Nicoletta ;
Spadoni, Isabella ;
Giusti, Sandra ;
Ait-Ali, Lamia ;
Sicari, Rosa ;
Andreassi, Maria Grazia .
STROKE, 2007, 38 (07) :2070-2073
[10]   A QUANTITATIVE ASSESSMENT OF PLASMA HOMOCYSTEINE AS A RISK FACTOR FOR VASCULAR-DISEASE - PROBABLE BENEFITS OF INCREASING FOLIC-ACID INTAKES [J].
BOUSHEY, CJ ;
BERESFORD, SAA ;
OMENN, GS ;
MOTULSKY, AG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (13) :1049-1057